7 completed, 5 recruiting, 2 terminated, 2 unknown. 9 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Anal Squamous Cell Carcinoma: new trials by email Literature Review of Anal Squamous Cell Carcinoma trials Research Report on Anal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of Pembrolizumab and Lenvatinib in Anal Squamous Cell Cancer Lenvatinib, Pembrolizumab - Anal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 17 | 2026-09-30 | 2026-07-02 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas EVOLVE104 - Bladder Cancer, Squamous Cell Carcinoma of the Lung | Phase 1 | Recruiting | EvolveImmune United, Inc | 160 | 2025-11-13 | 2026-09-15 |
| High Resolution Anuscopy Study HRA - Human Papilloma Virus, Anal Squamous Cell Carcinoma | Recruiting | Universitair Ziekenhuis Brussel | 500 | 2024-08-08 | 2025-02-19 | |
| MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach Radiotherapy - Low risk group, Radiotherapy - Standard risk group, Radiotherapy - Intermediate risk group - Anal Squamous Cell Carcinoma | Phase 2 | Recruiting | University Health Network, Toronto | 80 | 2023-09-29 | 2026-06-10 |
| A Global Record of Patients With Anal Squamous Cell Carcinoma With and Without HIV Infection Anal Squamous Cell Carcinoma, HIV Infections | Completed | Latin American Cooperative Oncology Group | 369 | 2023-06-09 | 2026-08-28 | |
| Adaptive Radiation in Anal Cancer Artificial Intelligence Guided Daily Radiotherapy Treatment Planning and Delivery, Mitomycin-C, 5-Fluorouracil - Anal Squamous Cell Carcinoma | Not applicable | Recruiting | Columbia University | 20 | 2023-05-18 | 2026-02-03 |
| Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers Regorafenib in combination with Tislelizumab - Anal Squamous Cell Carcinoma, Colorectal Neoplasms | Phase 2 | Withdrawn | Translational Research in Oncology | 2023-04-30 | 2023-06-07 | |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer Anoscopy, Biospecimen Collection, Capecitabine - AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 40 | 2022-08-09 | 2026-10-05 |
| Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients PD-1 inhibitor, concurrent chemoradiotherapy - Anal Canal Cancer Stage III, Anal Squamous Cell Carcinoma | Phase 3 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 102 | 2022-05-07 | 2022-05-16 |
| Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer online adaptive radiotherapy - Anal Cancer, Anal Carcinoma | Recruiting | Herlev Hospital | 205 | 2022-01-01 | 2023-09-25 | |
| PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients Toripalimab - Anal Canal Cancer, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Sun Yat-sen University | 25 | 2021-10-27 | 2024-12-03 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy GEN-011, IL-2, Fludarabine - Melanoma, Non-small Cell Lung Cancer | Phase 1 | Terminated | Genocea Biosciences, Inc. | 49 | 2020-11-11 | 2022-07-15 |
| 4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer Computed Tomography, Electronic Health Record Review, Follow-Up - Anal Squamous Cell Carcinoma, Stage 0 Anal Cancer AJCC v8 | Completed | M.D. Anderson Cancer Center | 41 | 2019-07-31 | 2024-02-20 | |
| Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer Capecitabine, Carboplatin, Cisplatin - Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma | Phase 2 | Unknown | ECOG-ACRIN Cancer Research Group | 91 | 2016-08-23 | 2023-06-22 |
| Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection Therapeutic Conventional Surgery - Anal Squamous Cell Carcinoma, HIV Infection | Phase 2 | Completed | AIDS Malignancy Consortium | 16 | 2015-04-01 | 2026-04-20 |
| Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays Rectal Adenocarcinoma, Anal Adenocarcinoma | Terminated | Castle Biosciences Incorporated | 3 | 2015-02-01 | 2018-01-25 | |
| Oral Rigosertib for Squamous Cell Carcinoma rigosertib - Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Completed | Traws Pharma, Inc. | 64 | 2013-03-01 | 2017-06-26 |
| Vectibix for the Treatment of Anal Cancer panitumumab, mytomicin C, 5-FU, radiation - Anal Squamous Cell Carcinoma | Phase 2 | Completed | Grupo Espanol Multidisciplinario del Cancer Digestivo | 58 | 2010-10-01 | 2018-05-16 |
| A Phase 1 Study in Participants With Advanced Cancer Prexasertib - Advanced Cancer, Squamous Cell Carcinoma | Phase 1 | Completed | Eli Lilly and Company | 150 | 2010-02-01 | 2016-05-10 |
Anus Neoplasms (19) · Anal Canal Carcinoma (4) · HIV Infections (3) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Squamous Cell (2) · Esophageal Squamous Cell Carcinoma (2) · Rectal Neoplasms (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1)
Anus Diseases (19) · Digestive System Diseases (19) · Digestive System Neoplasms (19) · Gastrointestinal Diseases (19) · Gastrointestinal Neoplasms (19) · Intestinal Diseases (19) · Intestinal Neoplasms (19) · Neoplasms by Site (19) · Rectal Diseases (19) · Colorectal Neoplasms (18) · Neoplasms (18) · Rectal Neoplasms (17) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Urogenital Diseases (5)
Fluorouracil (4) · Capecitabine (3) · Radiation (3) · Magnetic Resonance Spectroscopy (2) · Mitomycin (2) · dehydroftorafur (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Carboplatin (1) · Chemoradiotherapy (1) · Chromatin Immunoprecipitation Sequencing (1) · Cisplatin (1) · Colonoscopy (1) · Cyclophosphamide (1) · Fluorodeoxyglucose F18 (1) · Follow-Up Studies (1)
AIDS Malignancy Consortium (1) · Castle Biosciences Incorporated (1) · Columbia University (1) · ECOG-ACRIN Cancer Research Group (1) · Eli Lilly and Company (1) · EvolveImmune United, Inc (1) · Genocea Biosciences, Inc. (1) · Grupo Espanol Multidisciplinario del Cancer Digestivo (1) · Herlev Hospital (1) · Latin American Cooperative Oncology Group (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Sun Yat-sen University (1) · Translational Research in Oncology (1)
United States (11) · China (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Denmark (1) · Mexico (1) · Peru (1) · Spain (1) · Uruguay (1)
Aleydis Pisa, MD (1) · Antonio Arrivi, MD (1) · Benny Johnson (1) · Cathy Eng (1) · Clara Montagut, MD (1) · Emilio Fonseca, MD (1) · Eva S Serup-Hansen, MD, PhD (1) · Fernando Rivera, MD (1) · I Guasch, MD (1)
PMID 20354531, PMID 20956625, PMID 23578724, PMID 28453692, PMID 31534737, PMID 8874455, PMID 15629599, PMID 17103253, PMID 18430910, PMID 19801930, PMID 20436836, PMID 21240983, PMID 21514072, PMID 23484057, PMID 24035327, PMID 27044938, PMID 28055103, PMID 28223062, PMID 28463160, PMID 29643063, PMID 29755663, PMID 29878949, PMID 30264638, PMID 31288054, PMID 32530769, PMID 38528456, PMID 4830803, PMID 8348857, PMID 9164216
U01CA121947 (1), U10CA180820 (1), UM1CA121947 (1)